<DOC>
	<DOC>NCT01429675</DOC>
	<brief_summary>The purpose of this study is compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Bonviva (150mg Ibandronate, qd) after oral administration in healthy adult volunteers.</brief_summary>
	<brief_title>Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers</brief_title>
	<detailed_description>The number of patient is eighty-four. Patients were randomly assigned either a Bonviva tablet(150mg Ibandronate, qd) first, DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) Second or DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) first, Bonviva tablet(150mg Ibandronate, qd) second.</detailed_description>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>20 to 55 years of healthy volunteers Hypersensitivity Reaction about Ibandronate or other drugs(aspirin, antibiotics)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>